Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2026 15:06 ET | Source: Andrew Hillman Grant

Andrew Hillman Announces Andrew Hillman Grant for Biotech to Inspire the Next Generation of Innovators

DALLAS, April 02, 2026 (GLOBE NEWSWIRE) -- Andrew Hillman formally announces the launch of the Andrew Hillman Grant for Biotech, a forward-looking academic initiative designed to support...
April 02, 2026 13:40 ET | Source: Robbins Geller Rudman & Dowd LLP

IBRX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The case alleges ImmunityBio materially overstated Anktiva’s capabilities.
April 02, 2026 12:00 ET | Source: Regeneron Pharmaceuticals, Inc.

EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)

Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals New EYLEA HD dosing...
April 02, 2026 11:49 ET | Source: Research and Markets

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Intelligence Report 2026-2030: Industry Growth Driven by Personalized Treatment Adoption

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers a...
April 02, 2026 11:45 ET | Source: SPIE SA

SPIE signs an agreement for the acquisition of BLOCK Group in the Czech Republic

Cergy, April 2nd, 2026 – SPIE, the independent European leader in multi-technical services in the areas of energy and communications, announces the signing of an agreement for the acquisition of BLOCK...
April 02, 2026 11:45 ET | Source: Transgene S.A.

Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer

Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
April 02, 2026 11:00 ET | Source: A-Alpha Bio

Tamarind Bio Partners with A-Alpha Bio to Streamline Experimental Validation for AI-Enabled Antibody Discovery

SAN FRANCISCO and SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Tamarind Bio, an AI platform providing access to state-of-the-art computational biology tools, and A-Alpha Bio, a synthetic biology and...
April 02, 2026 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform

LOS ANGELES, April 02, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology and AI-driven...
April 02, 2026 08:30 ET | Source: Onconetix, Inc.

Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update

Realbotix Announces Expected Delivery of 19 Robots in March, April, and May 2026 as it Scales Production Capacity; Onconetix recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a...
April 02, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...